© 2004 European Society for Medical Oncology
Original Article |
Safety of sentinel node biopsy in pregnant patients with breast cancer
1 Division of Senology, 2 Unit of Medical Physics and 3 Division of Nuclear Medicine, European Institute of Oncology, Milan, Italy
* Correspondence to: Dr G. Paganelli, Division of Nuclear Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. Tel: +39-0257-489043; Fax: +39-0257-489208; Email: direzione.mnu{at}ieo.it
Background: Lymphoscintigraphy (LS) and sentinel lymph node biopsy (SLNB) have typically been contraindicated for pregnant patients diagnosed with breast cancer because they are considered unsafe.
Patients and methods: Twenty-six premenopausal non-pregnant patients who were candidates for LS underwent peritumoral injection of 
12 MBq of 99mTc-HSA nanocolloids. Static [15 min and 16 h post-injection (p.i.)] and whole-body (16 h p.i.) scintigraphic images were acquired. Activity concentration in the urine (0–2, 2–4, 4–8, 8–16 h p.i.) was evaluated by a gamma-counter. Activity in the bloodstream was measured at 4 and 16 h p.i. Thermoluminescent dosimeters (TLD) were placed, before tracer injection, on the injection site, between injection site and epigastrium (two points), and on the epigastrium, umbilicus and hypogastrium, and were removed before surgery.
Results: Scintigraphic images showed no radiotracer concentration except in the injection site and in the sentinel node. In all patients, the total activity excreted within the first 16 h was <2% of the injected activity. Activity in the blood pool was, at each time point, <1% of the injected activity. In 23 of 26 patients, all absorbed dose measurements were lower than the sensitivity of the TLD (<10 µGy); in the remaining three patients, the absorbed doses at the level of epigastrium, umbilicus and hypogastrium were in the following ranges: 40–320, 120–250 and 30–140 µGy, respectively.
Conclusions: According to our standard technique (12 MBq of 99mTc-HAS), LS and SLNB can be performed safely during pregnancy, since the very low prenatal doses from this diagnostic procedure, when properly performed, do not significantly increase the risk of prenatal death, malformation or mental impairment.
Key words: breast cancer, lymphoscintigraphy, pregnancy, radiation protection, sentinel node
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. H. Lyman, K. J. Van Zee, and S. B. Edge Impact and Remaining Challenges in the Use of Sentinel Lymph Node Biopsy in Early-stage Breast Cancer ASCO Educational Book, January 1, 2009; 2009(1): 346 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Pandit-Taskar, L. T. Dauer, L. Montgomery, J. St. Germain, P. B. Zanzonico, and C. R. Divgi Organ and Fetal Absorbed Dose Estimates from 99mTc-Sulfur Colloid Lymphoscintigraphy and Sentinel Node Localization in Breast Cancer Patients J. Nucl. Med., July 1, 2006; 47(7): 1202 - 1208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. H. Lyman, A. E. Giuliano, M. R. Somerfield, A. B. Benson III, D. C. Bodurka, H. J. Burstein, A. J. Cochran, H. S. Cody III, S. B. Edge, S. Galper, et al. American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer J. Clin. Oncol., October 20, 2005; 23(30): 7703 - 7720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Dubernard, J. R. Garbay, R. Rouzier, and S. Delaloge Safety of sentinel node biopsy in pregnant patients Ann. Onc., June 1, 2005; 16(6): 987 - 987. [Full Text] [PDF]
|
|
|
|
|
|
G. Paganelli, M. Cremonesi, M. Ferrari, G. Trifiro, O. Gentilini, and A. Luini Reply to the Letter to the Editor on Safety of sentinel node biopsy in pregnant patients, by G. Dubernard et al. (Ann Oncol 2005; 16: 987) Ann. Onc., June 1, 2005; 16(6): 987 - 988. [Full Text] [PDF]
|
|
|
|
|
|
I. Tek, A. Buyukcelik, B. Yalcin, and H. Akbulut Lymphoscintigraphy in pregnant patients with breast cancer: is it really safe? Ann. Onc., April 1, 2005; 16(4): 674 - 674. [Full Text] [PDF]
|
|
|
|
|
|
G. Paganelli, M. Ferrari, M. Cremonesi, O. Gentilini, and G. Trifiro Optimised lymphoscintigraphy in pregnant patients with breast cancer is safe Ann. Onc., April 1, 2005; 16(4): 674 - 675. [Full Text] [PDF]
|
|